drugset / Trial / NCT07057778
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
Phase 2
Not yet recruiting
120 enrolled
Peking University People's Hospital
Beijing Friendship Hospital · collabBeijing Hospital · collabBeijing Tongren Hospital · collabNavy General Hospital, Beijing · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant/relapsed ITP.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-12-30
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iguratimod | Small molecule | 25 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 100 mg | — |